Protocol Ledger

NCT06061094 · Phase II · RECRUITING

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

Interventional Phase II clinical trial protocol NCT06061094 sponsored by Goethe University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-14 Enrollment: 220 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06061094
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)220 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06061094
Protocol FieldVerified Registry Value
NCT IdentifierNCT06061094
Consolidated Lead SponsorGoethe University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment220 participants (ESTIMATED)
Registered Start Date2023-07-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06061094
Hospital Research SiteLocationSite Profile
Charité Universitätsmedizin BerlinBerlin, GermanyOpen Hospital Dossier ->
Universitätsklinikum BonnBonn, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI